These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 2764751)

  • 1. [Myasthenia gravis: treatment with thymectomy, corticoids and plasmapheresis].
    Dias-Tosta E; Morato-Fernandes RN
    Arq Neuropsiquiatr; 1989 Mar; 47(1):39-50. PubMed ID: 2764751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myasthenia gravis: effect of immunoactive therapies.
    Fornádi L; Horváth R; Bárdosi Z; Szobor A
    Acta Med Hung; 1994; 50(1-2):83-92. PubMed ID: 7638045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effects of plasmapheresis before thymectomy on the outcome in myasthenia gravis.
    Nagayasu T; Yamayoshi T; Matsumoto K; Ide N; Hashizume S; Nomura M; Muraoka M; Tagawa T; Akamine S; Oka T
    Jpn J Thorac Cardiovasc Surg; 2005 Jan; 53(1):2-7. PubMed ID: 15724495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The course of myasthenia gravis in patients treated with corticosteroids, azathioprine, and plasmapheresis.
    Cornelio F; Peluchetti D; Mantegazza R; Sghirlanzoni A; Collarile C
    Ann N Y Acad Sci; 1987; 505():517-25. PubMed ID: 3479934
    [No Abstract]   [Full Text] [Related]  

  • 5. Myasthenia gravis and pregnancy.
    Burke ME
    J Perinat Neonatal Nurs; 1993 Jun; 7(1):11-21. PubMed ID: 8336287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Myasthenia gravis. Clinical and therapeutic evaluation of 55 cases].
    Werneck LC; Teive HA
    Arq Neuropsiquiatr; 1987 Dec; 45(4):379-90. PubMed ID: 3329506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunological and therapeutic aspects of myasthenia gravis (author's transl)].
    Ghezzi M; Taiuti R; Marconi G
    Riv Patol Nerv Ment; 1981; 102(1):12-28. PubMed ID: 6285444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of plasmapheresis in preparing myasthenic patients for thymectomy: initial results.
    Spence PA; Morin JE; Katz M
    Can J Surg; 1984 May; 27(3):303-5. PubMed ID: 6722680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intensive care in myasthenic and cholinergic crises].
    Popova LM; Piradov MA
    Anesteziol Reanimatol; 1996; (2):13-5. PubMed ID: 8754165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Usefulness of plasmapheresis before thymectomy in the management of myasthenia gravis].
    Iváñez V; Díez-Tejedor E; Lara M; Barreiro P
    Neurologia; 1994; 9(7):277-81. PubMed ID: 7946422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Myasthenia gravis: clinical and surgical treatment].
    Werneck LC; Moreira PR
    Arq Neuropsiquiatr; 1991 Dec; 49(4):409-17. PubMed ID: 1842190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The therapy of myasthenia gravis pseudoparalytica].
    Baumgartner RW; Waespe W
    Dtsch Med Wochenschr; 1991 Jan; 116(4):148-54. PubMed ID: 1988277
    [No Abstract]   [Full Text] [Related]  

  • 13. The outcome of thymectomy in nonthymomatous myasthenia gravis.
    Huang MH; King KL; Hsu WH; Huang BS; Hsu HK; Wang LS; Chien KY
    Surg Gynecol Obstet; 1988 May; 166(5):436-40. PubMed ID: 3363464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic strategy in myasthenia gravis].
    Tranchant C
    Rev Neurol (Paris); 2009 Feb; 165(2):149-54. PubMed ID: 19233080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The course of myasthenia gravis with systemic lupus erythematosus.
    Bekircan-Kurt CE; Tuncer Kurne A; Erdem-Ozdamar S; Kalyoncu U; Karabudak R; Tan E
    Eur Neurol; 2014; 72(5-6):326-9. PubMed ID: 25323839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Splenectomy in the treatment of severe generalized myasthenia gravis (first experience)].
    Kuzin MI; Shkrob OS; Gekht BM; Vetshev PS; Shagal DI; Zaĭrat'iants OV; Khodzhaev ZSh; Ippolitov IKh
    Khirurgiia (Mosk); 1990 Aug; (8):95-9. PubMed ID: 2259184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefit of modified plasmapheresis in the management of myasthenia gravis: a case report.
    Talabi OA; Abjah UM; Ocheni S; Akinyemi OA; Aken'ova YA; Ogunniyi A
    Niger J Med; 2006; 15(2):162-4. PubMed ID: 16805175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of autoimmune myasthenia gravis.
    Richman DP; Agius MA
    Neurology; 2003 Dec; 61(12):1652-61. PubMed ID: 14694025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of myasthenia gravis].
    Martínez Castrillo JC; Mariscal A
    Med Clin (Barc); 1993 Nov; 101(18):693-6. PubMed ID: 8114526
    [No Abstract]   [Full Text] [Related]  

  • 20. Two-year outcome of thymectomy with or without immunosuppressive treatment in nonthymomatous myasthenia gravis and its effect on regulatory T cells.
    Jakubíková M; Piťha J; Marečková H; Týblová M; Nováková I; Schutzner J
    J Neurol Sci; 2015 Nov; 358(1-2):101-6. PubMed ID: 26320610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.